]>
IRCT138805192326N1 IRCT 2010-09-28 Vice-chancellery of Research Affairs of Shiraz University of Medical Sciences Assessment of subconjunctival bevacizumab effect on the postoperative healing course and recurrence of excised pterygium Assessment of subconjunctival bevacizumab effect on the postoperative healing course and recurrence of excised primary pterygium in patients referring to ophthalmology clinics 2009-08-15 anticipated 32 Complete https://irct.ir/trial/1973 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. N/A pterygium. Intervention 1: Intervention in cases: after excision of pterygium and rotational conjunctival flap,5 mg (0.2ml) of bevacizumab injected subconjunctivally in inferior fornix, and in the first post operative week additional 2.5mg of bevacizumab again injected in subconjunctival area in inferior fornix. Intervention 2: Intervention in controls: after excision of pterygium and rotational conjunctival flap, 0.2 ml of balanced salt solution, injected subconjunctivally in inferior fornix.
public Mohammad Banifatemi
Department of ophthalmology, Khalili hospital, Khalili street
Shiraz Iran (Islamic Republic of) +98 71 1647 1479 mbanifatemi@gmail.com Shiraz university of medical sciences scientific Mohammad Banifatemi
Department of ophthalmology, Khalili hospital, Khalili St.
Shiraz Iran (Islamic Republic of) +98 71 1647 1479 mbanifatemi@gmail.com Shiraz university of medical sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Inclusion criteria: the patients with primary pterygium referring to the ophthalmology clinics, affiliated to Shiraz University of Medical Sciences, that want pterygium removal. Exclusion criteria: glaucoma, regurgitation from lacrimal punctum (any indication of nasolacrimal obstruction), patients that seems not coming for follow-up exams during study, not treated diabetic patients, autoimmune diseases, pregnant patients, patients with ocular surface diseases or infections, two headed pterygium, previous limbal surgery, previous pterygial surgery. no limit no limit Both H18.4 corneal degeneration Treatment - Drugs Placebo Intervention in cases: after excision of pterygium and rotational conjunctival flap,5 mg (0.2ml) of bevacizumab injected subconjunctivally in inferior fornix, and in the first post operative week additional 2.5mg of bevacizumab again injected in subconjunctival area in inferior fornix. Intervention in controls: after excision of pterygium and rotational conjunctival flap, 0.2 ml of balanced salt solution, injected subconjunctivally in inferior fornix. Recurrence of pterygium. Timepoint: 1 month, 3 months, 6 months after operation. Method of measurement: Slit lamp examination and measuring the size of recurrent pterygial tissue on cornea. Healing of the surgical wound. Timepoint: 1 week,1 month. Method of measurement: observing erythema, subconjunctival hemorrhage, corneal epithelial defect, tearing, photophobia of the patients. Vice-chancellery of Research Affairs of Shiraz University of Medical Sciences Approved 1389-05-21 Shiraz university of medical sciences ethics committee 7th floor,Shiraz university of medical sciences, Zand St. Shiraz Iran (Islamic Republic of)